CONTRASTING FIBRINOLYTIC RESPONSES IN TYPE-1 (INSULIN-DEPENDENT) AND TYPE-2 (NON-INSULIN-DEPENDENT) DIABETES

被引：46
作者：
WALMSLEY, D [1 ]
HAMPTON, KK [1 ]
GRANT, PJ [1 ]
机构：
[1] UNIV LEEDS,GEN INFIRM,DEPT MED,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND
来源：
DIABETIC MEDICINE | 1991年 / 8卷 / 10期
关键词：
DIABETES-MELLITUS; COMPLICATIONS; FIBRINOLYSIS;
D O I：
10.1111/j.1464-5491.1991.tb01536.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
To study fibrinolysis in relation to microvascular diabetic complications, 20 control subjects were compared with 50 Type 1 (insulin-dependent) diabetic patients of similar age, 20 with no complications, 17 with laser-treated retinopathy, and 13 with neuropathy and retinopathy. None were smokers, hypertensive or had macrovascular disease. Pre- and post-venous occlusion blood samples for tests of fibrinolysis were taken. Median (interquartile range) basal tissue plasminogen activator (t-PA) activity was lower in control subjects (100 (< 100-100) IU l-1) than diabetic patients (uncomplicated 145 (100-280) IU l-1, p = 0.015; retinopathy 180 (100-228) IU l-1, p = 0.037; neuropathy 210 (125-310) IU l-1, p = 0.004, respectively). Basal t-PA inhibition (PAI-1 activity) was higher in control subjects (5.9 (4.5-9.5) kIU l-1) than diabetic patients (uncomplicated 4.0 (3.3-5.0) kIU l-1, p = 0.001; retinopathy 4.5 (3.1-6.3) kIU l-1, p = 0.058; neuropathy 4.0 (3.0-5.4) kIU l-1, p = 0.015, respectively). Post-venous occlusion t-PA antigen was higher in control subjects (10.2 (7.3-15.1) mu-g l-1) than neuropathic patients (5.5 (4.9-7.3) mu-g l-1, p = 0.004). Other tests showed a consistent, but non-significant, trend towards increased basal fibrinolysis in the Type 1 diabetic patients. The results indicate that Type 1 diabetic patients have enhanced basal fibrinolysis. The diminished response to venous occlusion in neuropathic patients is consistent with an endothelial cell defect. These findings are in marked contrast to those in 20 uncomplicated Type 2 diabetic patients who had diminished basal and post-venous occlusion fibrinolytic activity with high basal t-PA (13.4 (9.8-16.8) mu-g l-1) and PAI-1 (26.5 (12.4-39.6) mu-g l-1) antigen. The differing fibrinolytic responses may contribute to the heterogeneous nature of vascular disease in diabetes.
引用
收藏
页码：954 / 959
页数：6
相关论文
共 40 条
[31]  
Jones RL, Fibrinopeptide A in diabetes mellitus. Relation to levels of blood glucose, fibrinogen disappearance, and haemodynamic changes, Diabetes, 34, pp. 836-843, (1985)
[32]  
Mehta J., Mehta P., Lawson D., Saldeen T., Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride levels, J Am Coll Cardiol, 9, pp. 263-268, (1987)
[33]  
Sundell JB, Dahlgren S., Ranby M., Lundin E., Stenling R., Nilsson TK, Reduction of elevated plasminogen activator inhibitor levels during modest weight loss, Fibrinolysis, 3, pp. 51-53, (1989)
[34]  
Stout RW, Vallance-Owen J., Insulin and atheroma, Lancet, 1, pp. 1078-1080, (1971)
[35]  
Jarrett RJ, Is insulin atherogenic?, Diabetologia, 31, pp. 71-75, (1988)
[36]  
Grant PJ, Ruegg M., Medcalf RL, Basal expression and insulin‐mediated induction of PAI‐1 mRNA in Hep G2 cells, Fibrinolysis, 5, pp. 81-86, (1991)
[37]  
Juhan-Vague I., Vague P., Alessi MC, Badier C., Valadier J., Aillaud MF, Et al., Relationships between plasma insulin, triglyceride, body mass index and plasminogen activator inhibitor 1, Diabete Metabol, 13, pp. 331-336, (1987)
[38]  
Juhan-Vague I., Vague P., Poisson C., Aillaud MF, Mendez C., Collen D., Effect of 24 hours of normoglycaemia on tissue‐type plasminogen activator plasma levels in insulin‐dependent diabetes, Thromb Haemostas, 51, pp. 97-98, (1984)
[39]  
Juhan-Vague I., Alessi MC, Fossat C., Declerck PJ, Kruithof EKO, Plasma determination of plasminogen activator inhibitor 1 antigen must be performed in blood collected on antiplatelet/anticoagulant mixture, Thromb Haemostas, 58, (1987)
[40]  
Reich E., Activation of plasminogen: a general mechanism for producing localized extracellular proteolysis, Molecular Basis of Biological Degradative Processes, pp. 155-169, (1978)
1234